Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine for prevention and/or treatment of respiratory syncytial virus infection

A technology of syncytial virus and respiratory tract, applied in the field of co-immune vaccines, can solve the problems of limited improvement and low level of neutralizing antibodies, achieve low cost, inhibit inflammation-related reactions, and enhance humoral immune responses

Active Publication Date: 2013-08-14
ADVACCINE SUZHOU BIOPHARMACEUTICALS CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the level of antibodies induced by it, especially the level of neutralizing antibodies is low
Although some studies have reported that the use of immunostimulators can improve the humoral immune response induced by DNA vaccines to a certain extent, but the improvement is limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine for prevention and/or treatment of respiratory syncytial virus infection
  • Vaccine for prevention and/or treatment of respiratory syncytial virus infection
  • Vaccine for prevention and/or treatment of respiratory syncytial virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1, the preparation of DNA vaccine

[0044] Respiratory syncytial virus surface glycoprotein G (referred to as G protein) is obtained through the method of whole gene synthesis after codon optimization of eukaryotic cells. The DNA fragment (as shown in sequence 1 in the sequence listing, wherein the 7th-708th is the coding sequence of G protein, the protein shown in sequence 2 in the coding sequence listing) containing the gene encoding the surface glycoprotein G of respiratory syncytial virus The endonucleases EcoR I and Xba I were digested, and connected to the eukaryotic expression vector proVAX (Xiaogang Du, Guoxing Zheng, Huali Jin, Youmin Kang, Junpeng Wang, Chong Xiao, Shuo Zhang, Mingyu Liu, Lin Zhao, Aoshuang Chen and Bin Wang. The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination. J. Gene Medicine, 2007; 9: 136-146.), forming recombinant plasmids. After the obtained recombinant plasmid was digeste...

Embodiment 2

[0048] Embodiment 2, the preparation of subunit vaccine

[0049] Respiratory syncytial virus surface glycoprotein G was obtained by total gene synthesis after codon optimization in Escherichia coli cells. The DNA fragment (as shown in sequence 3 in the sequence listing, wherein the 7-708th is the coding sequence of G protein, the protein shown in sequence 2 in the coding sequence listing) containing the gene encoding the surface glycoprotein G of respiratory syncytial virus It was digested with endonucleases EcoR I and Xho I, and connected to the prokaryotic expression vector pET-28a(+) that had been cut with the same restriction enzymes to form a recombinant plasmid. After the obtained recombinant plasmid was digested with restriction endonucleases EcoR I and Xho I, the target fragment with a size of about 708 bp and a vector fragment with a size of about 5400 bp were obtained by agarose gel electrophoresis, which were consistent with the expected results. It was further confi...

Embodiment 3

[0054] Example 3, Detection of Antibody Levels After DNA Vaccine and / or Subunit Vaccine Immunization Model Animals

[0055] 1. Experiments on DNA vaccine and / or subunit vaccine immunization model animals

[0056] Model animals: 6-8 week-old female BALB / c mice, purchased from Beijing Huafukang Biotechnology Co., Ltd., clean grade, divided into 9 groups, 5 mice in each group.

[0057] Vaccines and controls for immunization: PBS, formalin inactivated vaccine FI-RSV (10 7 TCID 50 RSV virus (US ATCC, catalog no. VR-26 TM , after reaction with formaldehyde for 72 hours at 37°C, purified by high-speed centrifugation at 50,000 g for 1 hour), DNA vaccine proVAX / G, subunit vaccine His-G, DNA vaccine empty vector control proVAX and subunit vaccine His-G, etc. Mass mixture, equal mass mixture of DNA vaccine proVAX / G and ovalbumin OVA (product of Sigma Company) of irrelevant protein, equal mass mixture of inventive technology group (common immunization) DNA vaccine proVAX / G and subunit ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a co-immune vaccine for prevention and / or treatment of diseases caused by respiratory syncytial virus infection. The vaccine is composed of a DNA vaccine and a subunit vaccine. The DNA vaccine is a recombinant expression vector containing an encoding gene of a protein as shown in a sequence 2 in a sequence table. The subunit vaccine is a protein as shown in the sequence 2 in the sequence table. Experimental results show that the co-immune vaccine provided by the present invention can enhance the humoral immune response of immune animals, also inhibit too strong cellular immune response, effectively inhibit inflammation, protect lung tissues of mammalians and prevent function from destruction of RSV infection.

Description

technical field [0001] The invention relates to a co-immune vaccine for preventing and / or treating diseases caused by respiratory syncytial virus infection, in particular to a co-immune vaccine composed of a DNA vaccine and a subunit vaccine for preventing and / or treating respiratory syncytial virus Co-immune vaccines for diseases caused by infection. Background technique [0002] Respiratory syncytial virus (RSV) is a member of the genus Pneumovirus in the Paramyxoviridae family. It is a non-segmented single-stranded negative-sense RNA virus and is divided into two subtypes, A and B. The RSV virus is about 120-300 nanometers in size, has an envelope, consists of 15222 nucleotides, and encodes 10 main proteins, which are composed of three transmembrane proteins (G, F and SH), two matrix proteins (M and M 2), three nucleocapsid proteins (N, P and L) and two non-structural proteins (NS1 and NS2). RSV is an important pathogen causing acute lower respiratory tract infections s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K39/155A61P31/14A61P29/00
CPCC12N2760/18534A61K39/155A61K48/00A61K2039/545A61K39/12A61K2039/53C07K14/135C07K14/005C12N2760/18522A61P31/14C12N7/00C12N2760/18571
Inventor 王宾陈璇俞庆龄
Owner ADVACCINE SUZHOU BIOPHARMACEUTICALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com